Path-30. Clinical Outcomes And Predictive Biomarkers For Idh-Wildtype Glioblastomas Developing Hypermutation Following Temozolomide Treatment
Jacob Young,Calixto-Hope Lucas,Nadeem Al-Adli,Rohit Gupta,Ramin Morshed,Jasper Wu,Ajay Ravindranathan,Anny Shai,Nancy Ann Oberheim-Bush,Jennie Taylor,John de Groot,Javier Villanueva-Meyer,Melike Pekmezci,Arie Perry,Andy Bollen,Philip Theodosopoulos,Manish Aghi,Edward Chang,Shawn Hervey-Jumper,David Raleigh,Aaron Diaz,Joseph Costello,Jennifer Clarke,Nicholas Butowski,Joanna Phillips,Susan Chang,Mitchel Berger,David Solomon
DOI: https://doi.org/10.1093/neuonc/noae165.0729
2024-11-29
Neuro-Oncology
Abstract:Current standard of care for IDH-wildtype glioblastoma (GBM) includes maximal safe resection, adjuvant radiation, and chemotherapy with the alkylating agent temozolomide. A subset of gliomas treated with temozolomide develop somatic hypermutation with a predominance of C>T transitions due to the alkylation effects on DNA. However, the frequency of occurrence, clinical ramifications, and predictive biomarkers for developing temozolomide-induced hypermutation (TMZ-HM) in GBM are unknown. Here we performed comprehensive histopathologic, genomic, and epigenomic evaluation of paired initial and recurrent GBM from 106 patients. Seven patients (7%) developed hypermutation at time of first recurrence, while an additional five patients (5%) developed hypermutation at a subsequent recurrence. Patients who developed TMZ-HM had a significantly longer interval between initial surgery and first recurrence (27.8 vs. 9.9 months, p<0.001). In contrast to IDH-mutant gliomas where TMZ-HM is associated with poor prognosis, those patients with IDH-wildtype GBM who developed TMZ-HM had significantly longer overall survival from both initial surgery (67.9 vs. 20.3 months, p<0.001) and from time of recurrence after development of hypermutation (30.9 vs. 9.5 months, p=0.001). There was no difference in oncogenic alteration frequency in initial GBM that subsequently developed TMZ-HM. However, 4 specific CpG sites out of 12 total interrogated sites in the promoter region of MGMT (a DNA repair enzyme) and 5 specific CpG sites in the promoter region of KCNQ1DN (a negative regulator of c-Myc) were significantly more hypermethylated in those GBM that developed TMZ-HM. We then generated a weighted risk score across these CpG sites that can be used to prospectively identify GBM likely to develop TMZ-HM associated with favorable survival. In summary, patients with GBM that develop TMZ-HM follow a more favorable clinical course, and specific MGMT and KCNQ1DN promoter hypermethylation patterns could serve as a biomarker to identify these patients who may potentially benefit from extended alkylating chemotherapy treatment.
oncology,clinical neurology